Global Vigabatrin Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Vigabatrin Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Vigabatrin is a medication used to treat epilepsy. It became available as a generic medication in 2019. It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.
Vigabatrin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Vigabatrin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Infantile Spasms (IS) and Partial-Onset Seizures are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Vigabatrin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Vigabatrin key manufacturers include Sanofi, Benta Pharma Industries, Dr. Fisher Farma, Lundbeck, Novartis, Perrigo, Grindeks, Endo International and Amneal Pharma, etc. Sanofi, Benta Pharma Industries, Dr. Fisher Farma are top 3 players and held % sales share in total in 2022.
Vigabatrin can be divided into Tablet and Powder, etc. Tablet is the mainstream product in the market, accounting for % sales share globally in 2022.
Vigabatrin is widely used in various fields, such as Infantile Spasms (IS), Partial-Onset Seizures and Refractory Complex Partial Seizures,, etc. Infantile Spasms (IS) provides greatest supports to the Vigabatrin industry development. In 2022, global % sales of Vigabatrin went into Infantile Spasms (IS) filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Vigabatrin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi
Benta Pharma Industries
Dr. Fisher Farma
Lundbeck
Novartis
Perrigo
Grindeks
Endo International
Amneal Pharma
Cipla
Upsher-Smith
Segment by Type
Tablet
Powder
Infantile Spasms (IS)
Partial-Onset Seizures
Refractory Complex Partial Seizures
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Vigabatrin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Vigabatrin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Vigabatrin industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Vigabatrin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Vigabatrin introduction, etc. Vigabatrin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Vigabatrin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Vigabatrin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Vigabatrin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Infantile Spasms (IS) and Partial-Onset Seizures are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Vigabatrin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Vigabatrin key manufacturers include Sanofi, Benta Pharma Industries, Dr. Fisher Farma, Lundbeck, Novartis, Perrigo, Grindeks, Endo International and Amneal Pharma, etc. Sanofi, Benta Pharma Industries, Dr. Fisher Farma are top 3 players and held % sales share in total in 2022.
Vigabatrin can be divided into Tablet and Powder, etc. Tablet is the mainstream product in the market, accounting for % sales share globally in 2022.
Vigabatrin is widely used in various fields, such as Infantile Spasms (IS), Partial-Onset Seizures and Refractory Complex Partial Seizures,, etc. Infantile Spasms (IS) provides greatest supports to the Vigabatrin industry development. In 2022, global % sales of Vigabatrin went into Infantile Spasms (IS) filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Vigabatrin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi
Benta Pharma Industries
Dr. Fisher Farma
Lundbeck
Novartis
Perrigo
Grindeks
Endo International
Amneal Pharma
Cipla
Upsher-Smith
Segment by Type
Tablet
Powder
Segment by Application
Infantile Spasms (IS)
Partial-Onset Seizures
Refractory Complex Partial Seizures
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Vigabatrin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Vigabatrin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Vigabatrin industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Vigabatrin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Vigabatrin introduction, etc. Vigabatrin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Vigabatrin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices